Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 287, Issue 2 31-2, 2004, Pages

  Barber, Rachael ^a   Baillie, George S ^b   Bergmann, Reinhard ^c   Shepherd, Malcolm C ^b   Sepper, Ruth ^d   Houslay, Miles D ^b   Van Heeke, Gino ^a,e  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Institute of Experimental and Clinical Medicine Tallinn   (Estonia)

^e Respiratory Disease TA   (United Kingdom)

Author keywords

CAMP specific phosphodiesterase family type 4; Chronic obstructive pulmonary disease; Inflammation

Indexed keywords

ISOPROTEIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV A10; PHOSPHODIESTERASE IV A7; PHOSPHODIESTERASE IV B1; PHOSPHODIESTERASE IV B2; PHOSPHODIESTERASE IV D1; PHOSPHODIESTERASE IV D2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; INFLAMMATORY CELL; LUNG ALVEOLUS MACROPHAGE; MALE; MONOCYTE; NEUTROPHIL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING HABIT; T LYMPHOCYTE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ALTERNATIVE SPLICING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; ISOENZYMES; MONOCYTES; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMOKING; T-LYMPHOCYTES;

EID: 3242726932     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00384.2003     Document Type: Article

References (42)

1. Barnes PJ. New concepts in chronic obstructive pulmonary disease. Annu Rev Med 54: 113-129, 2003.
2. Beavo JA and Brunton LL. Cyclic nucleotide research: still expanding after half a century. Nat Rev Mol Cell Biol 3: 710-718, 2002.
3. Bolger GB, Peden AH, Steele MR, MacKenzie C, McEwan DG, Wallace DA, Huston E, Baillie GS, and Houslay MD. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem 278: 33351-33363, 2003.
4. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, and Beume R. In vivo efficacy in airway disease models of Roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 297: 280-290, 2001.
5. Burnouf C and Pruniaux MP. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Design 8: 1255-1296, 2002.
6. Conti M and Jin SLC. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63: 1-38, 1999.
7. Conti M, Richter W, Mehats C, Livera G, Park JY, and Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278: 5493-5496, 2003.
8. Dyke HJ and Montana JG. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 11: 1-13, 2002.
9. Gantner F, Tenor H, Gekeler V, Schudt C, Wendel A, and Hatzelmann A. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. J Allergy Clin Immunol 100: 527-535, 1997.
10. Giembyez MA. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis 57: 48-64, 2002.
11. Giembycz MA, Corrigan CJ, Seybold J, Newton R, and Barnes PJ. Identification of cyclic AMP phosphodiesterases 3, 4, and 7 in human CD4 and CD8 T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118: 1945-1958, 1996.
12. a. Global Initiative for Chronic Obstructive Lung Disease. Retrieved January 26, 2004, from http://www.goldcopd.com
13. Hansen G, Jin SLC, Umetsu DT, and Conti M. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci USA 95: 6751-6756, 2000.
14. Hatzelman A and Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor Roflumilast in vitro. J Pharmacol Exp Ther 297: 267-279, 2001.
15. A cAMP phosphodiesterase (HSPDE4A7) and localisation of the gene to the p13.2-q12 region of human chromosome 19. Biochem J 308: 683-691, 1995.
16. Houslay MD. Intracellular targeting and regulation of PDE4 cAMP specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 69: 249-315, 2001.
17. Houslay MD and Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370: 1-18, 2003.
18. Huang Z, Ducharme Y, Macdonals D, and Robichaud A. The next generation of PDE4 inhibitors. Curr Opin Chem Biol 5: 432-438, 2001.
19. Huston E, Beard M, McCallum F, Pyne NJ, Vandenabeele P, Scotland G, and Houslay MD. The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3-interaction domain by caspase-3: consequences for altered intracellular distribution. J Biol Chem 275: 28063-28074, 2000.
20. Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma. Chest 117: 251S-260S, 2000.
21. Jin SLC and Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses. Proc Natl Acad Sci USA 99: 7628-7633, 2002.
22. Kazlauskas A, Poellinger L, and Pongratz I. Two distinct regions of the immunophilin-like Protein XAP2 regulate dioxin receptor function and interaction with hsp90. J Biol Chem 277: 11795-11801, 2002.
23. Landells LJ, Szilagy CM, Jones NA, Banner KH, Allen JM, Doherty A, O'Connor BJ, Spina D, and Page CP. Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CDE8 lymphocytes from healthy and asthmatic subjects. Br J Pharmacol 133: 722-729, 2001.
24. LeJeune IR, Shepherd M, Van Heeke G, Houslay MD, and Hall IP. cAMP-dependent transcriptional upregulation of phosphodiesterase 4D5 in human airway smooth muscle cells. J Biol Chem 277: 35980-35989, 2002.
25. Li L, Yee C, and Beavo JA. CD3 and CD28-dependent induction of PDE7 is required for T-cell activation. Science 283: 848-851, 1999.
26. Ma D, Wu P, Egan RW, Billah MM, and Wang P. Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol Pharmacol 55: 50-57, 1999.
27. Mackenzie SJ and Houslay MD. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element- binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem J 347: 571-578, 2000.
28. Mackenzie SJ, Yarwood SJ, Peden AH, Bolger GB, Vernon RG, and Houslay MD. Stimulation of p70S6 kinase via a growth hormone-controlled phosphatidylinositol 3-kinase pathway leads to the activation of a PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadipocytes. Proc Natl Acad Sci USA 95: 3549-3554, 1998.
29. Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, Grous M, Torphy TJ, and Barnette MS. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 128: 1393-1398, 1999.
30. Manning CD, McLaughlin MM, Livi GP, Cielinski LB, Torphy TJ, and Barnette MS. Prolonged β-adrenoceptor stimulation upregulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. J Pharmacol Exp Ther 276: 810-818, 1996.
31. Marchmont RJ and Houslay MD. A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. Biochem J 187: 381-392, 1980.
32. McPhee I, Yarwood SJ, Huston E, Scotland G, Beard MB, Ross MH, Houslay ES, and Houslay MD. Association with the src family tyrosyl kinase lyn triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B: consequences for rolipram inhibition. J Biol Chem 274: 11796-11810, 1999.
33. 2-adrenoreceptor signaling by targeting cyclic AMP degradation. Science 298: 834-836, 2002.
34. 2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 110: 1045-1052, 2002.
35. Schmidt D, Dent G, and Rabe KF. Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 29: 99-109, 1999.
36. Soares AC, Souza DG, Pinho V, Vieira AT, Barsante MM, Nicoli JR, and Teixeira M. Impaired host defense to Klebsiella pneunomiae infection in mice treated with the PDE4 inhibitor rolipram. Br J Pharmacol 140: 855-862, 2003.
37. Tenor H, Hatzelmann A, Kupferschmidt R, Stanciu L, Djukanovic R, Schudt C, Wendel A, Church MK, and Shute JK. Cyclic nucleotide phosphodiesterase isozyme activity in human alveolar macrophages. Clin Exp Allergy 25: 625-633, 1995.
38. Thompson WJ and Appleman MM. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10: 311-316, 1971.
39. Torphy TJ. Phosphodiesterase isozymes. Molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157: 351-370, 1998.
40. Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, Nieman RB, and Compton CH. Ariflo (SB207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol 12: 131-135, 1999.
41. Wang P, Wu P, Ohleth KM, Egan RW, and Billah MM. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 56: 170-174, 1999.
42. Workshop summary and guidelines: investigative use of bronchoscopy, lavage, and bronchial biopsies in asthma and other airway diseases. J Allergy Clin Immunol 88: 808-814, 1991.